NCT05447702View on ClinicalTrials.gov

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2026

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Camrelizumab

Intravenous (IV) infusion

DRUG

Apatinib

po.

DRUG

Nab-paclitaxel

IV infusion.

DRUG

Epirubicin

IV infusion.

DRUG

Cyclophosphamide

IV infusion.

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

West China Hospital

OTHER